博舒替尼引起胸腔积液：病例报告及酪氨酸激酶抑制剂所致肺毒性的综述
Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.
作者信息
Moguillansky Natalia I, Fakih Hafiz Abdul Moiz, Wingard John R
机构信息
University of Florida, Pulmonary, Critical Care and Sleep Medicine, P.O. Box 100225 JHMHC, Gainesville, FL 32610-0225, USA.
University of Florida, UF Health Bone Marrow Transplant - Shands Hospital, 1515 SW Archer Rd, Suite #100, Gainesville, FL 32608, USA.
出版信息
Respir Med Case Rep. 2017 May 10;21:154-157. doi: 10.1016/j.rmcr.2017.05.003. eCollection 2017.
Tyrosine kinase inhibitors are known to cause pulmonary complications. We report a case of bosutinib related bilateral pleural effusions in a patient with chronic myeloid leukemia. Characteristics of the pleural fluid are presented. We also discuss other tyrosine kinase inhibitors induced pulmonary toxicities, including pulmonary hypertension and interstitial lung disease.
已知酪氨酸激酶抑制剂会引发肺部并发症。我们报告了一例慢性髓性白血病患者使用博舒替尼后出现双侧胸腔积液的病例。文中呈现了胸腔积液的特征。我们还讨论了其他酪氨酸激酶抑制剂诱发的肺部毒性，包括肺动脉高压和间质性肺疾病。
Zotero 插件